Zacks Research Analysts Increase Earnings Estimates for FOLD

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for shares of Amicus Therapeutics in a research report issued on Tuesday, April 1st. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.06 for the quarter, up from their previous forecast of $0.04. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.13 EPS, FY2026 earnings at $0.36 EPS, Q1 2027 earnings at $0.10 EPS and FY2027 earnings at $0.56 EPS.

Several other research firms have also commented on FOLD. Cantor Fitzgerald reiterated an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Morgan Stanley restated an "equal weight" rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, Wells Fargo & Company dropped their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $16.75.

Amicus Therapeutics Price Performance

FOLD traded down $0.50 during trading on Wednesday, reaching $7.50. 3,184,754 shares of the stock were exchanged, compared to its average volume of 2,535,352. Amicus Therapeutics has a 1 year low of $7.39 and a 1 year high of $12.65. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -41.67, a P/E/G ratio of 1.51 and a beta of 0.79. The business's 50 day moving average price is $9.12 and its two-hundred day moving average price is $9.85. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtus Fund Advisers LLC purchased a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $29,000. Covestor Ltd raised its position in shares of Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 2,312 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics in the third quarter valued at $55,000. GF Fund Management CO. LTD. purchased a new stake in Amicus Therapeutics during the fourth quarter valued at about $59,000. Finally, R Squared Ltd acquired a new stake in Amicus Therapeutics during the fourth quarter worth about $79,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.